Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HY05350 in MSLN-positive advanced solid tumors
NCT07083323Phase 2Recruiting
- Sponsor
- Sichuan Huiyu Pharmaceuticals
- Start
- Jul 2025
- Primary completion
- Mar 2028
- Modality
- Antibody Conjugates, Trispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of HY05350 in solid tumor (advanced stage), sponsored by Sichuan Huiyu Pharmaceuticals. Started Jul 2025; status: recruiting.
02
Drugs
HY05350
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT07083323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07083323.